Phosphatases of regenerating liver play a unique role in the growth and spread of cancers

Phosphatases of regenerating liver (PRLs) are a family of enigmatic proteins involved in cell growth and metabolism present in various species. From humans to fruit flies, they play a unique role in the growth of cancerous tumors and the spread of cancer throughout the body. New research emerging from McGill University is contributing to what is known about PRLs, which could potentially become an important tool in the development of cancer-fighting treatments.

Led by Kalle Gehring, a professor in the Department of Biochemistry and founding director of the McGill Centre for Structural Biology, the researchers focused on unraveling the mystery around PRLs.

It's important for us to study PRLs because they are so important in cancer. In some cancers such as metastatic colorectal cancer, the proteins are overexpressed up to 300-fold."

Kalle Gehring, Professor, Department of Biochemistry

Published in the Journal of Biological Chemistry, Prof. Gehring and his colleagues (with data collected at the Canadian Light Source (CLS) at the University of Saskatchewan) confirmed that not only PRLs exist in all kinds of single- and multi-cell animals, but that the role of PRLs in binding magnesium transporters is common among all studied species.

This overexpression of PRLs makes cancer cells more metastatic and drives the spread to other organs. This data could help to further the understanding of how these proteins influence human disease.

"What we learned is that they all bind the magnesium transporters in the same way," says Gehring. "We're excited because it helps us understand this pathway, and that will reveal new targets for drugs to prevent cancer progression."

Journal reference:

Fakih, R., et al. (2023). Burst kinetics and CNNM binding are evolutionarily conserved properties of phosphatases of regenerating liver. Journal of Biological Chemistry.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer